At around 11.30 AM, Nifty Pharma performs at 13,310.80 down by 8.95 points or 0.07%. The index has touched an intraday high of 13,418.60 and intraday low of 13,241.90 during early trading session on Monday.
Today, Natco Pharma has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.
On the trading index, 6 scrips were in advancing note whereas 4 scrips were performing in the decling note.
Cadila Healthcare was the top bull of index surging by 1.18% at Rs577.65.
Heavyweights Divi's Laboratories and Dr Reddy's were trading in the green by nearly 1% each.
Biocon (up 0.18%), Torrent Pharma (up 0.12%) and Alkem Laboratories (up 0.05%) were tradingin the flat note on the index. On 26th April, Biocon's subsidiary Biocon Biologics and Viatris receives European Commission approval for Biosimilar Bevacizumab.
Rest, all the scrips of the index were trading bearish dragging the Nifty 50 down.
Cipla was the top laggard of the index tumbling by 1.38% at Rs922.70 per piece.
Lupin (-0.02%), Sun Pharma (-0.38%), Aurobindo Pharma (-0.59%) all were trading on a bearish note.
The United States said on April 25 that it will send additional support to India to help in its fight against the coronavirus second wave.
A net incline of 1,37,188 cases recorded from the total active caseload in the last 24 hours.The five States of Maharashtra, Chhattisgarh, Uttar Pradesh, Karnataka and Kerala cumulatively account for 59.12% of India’s total Active Cases.